Comparison of $^{64}$Cu and $^{68}$Ga for Molecular Imaging of Atherosclerosis using the Apolipoprotein A-I Mimetic Peptide FAMP

Eiji Yahiro$^1$, Emi Kawachi$^2$, Shin-ichiro Miura$^{1,2,*}$, Takashi Kuwano$^1$, Satoshi Imaizumi$^1$, Atsushi Iwata$^1$, Koki Hasegawa$^2$, Tsuneo Yano$^{4,5}$, Yasuyoshi Watanabe$^6$, Yoshinari Uehara$^{1,2}$ and Keijiro Saku$^{1,2,*}$

$^1$Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
$^2$Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, Japan
$^3$Department of Pathology and Experimental Medicine, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan
$^4$Engineering Department, Industrial Equipment Division, Sumitomo Heavy Industries Ltd., Japan
$^5$Osaka University Graduate School of Medicine, Osaka, Japan
$^6$RIKEN Center for Life Science Technologies, Kobe, Japan

$^*$E.Y. and E.K. contributed equally to this work

Abstract

Background: Molecular imaging for detection of the atherosclerotic plaque burden has been highlighted as a modality for the diagnosis of atherosclerosis. We recently developed a novel and noninvasive positron emission tomography (PET) that was functionalized with an apolipoprotein (Apo) A-I mimetic peptide [known as FAMP (FAMP)] radiolabeled with gallium-68 ($^{68}$Ga) - 1, 4, 7, 10-tetraazaacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) - to specifically image the status of atherosclerotic plaque in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits (WHHL-MI).

Methods and Results: To achieve more sensitive molecular imaging, FAMP was modified with 4, 11 - bis (carboxymethyl) - 1, 4, 8, 11 - tetraazabicyclo (6.6.2) hexadecane (CB-TE2A) and radiolabeled with copper-64 ($^{64}$Cu) for PET, and the ability of $^{64}$Cu-CB-TE2A-FAMP to image plaque was compared with that of $^{68}$Ga-DOTA-FAMP. Japanese white normal (JW) and WHHL-MI rabbits were intravenously injected with $^{64}$Cu-CB-TE2A-FAMP or $^{68}$Ga-DOTA-FAMP, and subjected to continuous PET (25-30 MBq). Interestingly, $^{64}$Cu-CB-TE2A-FAMP was not taken up by atherosclerotic lesions in the aorta of WHHL-MI, whereas $^{68}$Ga-DOTA-FAMP was dramatically illuminated in the aorta of WHHL-MI. Moreover, $^{64}$Cu-CB-TE2A-FAMP was rapidly decomposed and $^{64}$Cu was excreted to the intestine, liver or urinary bladder in both JW and WHHL-MI rabbits.

Conclusions: These results demonstrated that FAMP may be a target molecule for atherosclerotic molecular imaging with $^{68}$Ga-DOTA, but not with $^{64}$Cu-CB-TE2A. The selection of a suitable radio-nuclide and chelator might be important for HDL functioning imaging.

Keywords: Molecular imaging; Positron emission tomography; Apolipoprotein A-I mimetic peptide; Watanabe heritable hyperlipidemic rabbits

Introduction

Cardiovascular disease is the leading cause of death in the world [1]. Atherosclerosis affects arterial blood vessels due to chronic inflammation and induces cardiovascular disease. Molecular imaging aims to identify and guide the treatment of vulnerable atherosclerotic plaque. A novel and noninvasive positron emission tomography (PET)-based method for imaging inflammatory plaque with $^{18}$F-fluorodeoxyglucose (FDG) is currently of interest in the clinical setting [2]. Although atherosclerotic disease may produce no or only mild diffuse uptake along the vessel wall in FDG-PET, both the sensitivity and molecular specificity for targeting atherosclerosis by FDG-PET are relatively low [3-5].

Since the physical interactions between apolipoprotein A-I (Apo A-I) and ATP-binding cassette transporter 1 (ABCA1) modulate not only binding to Apo A-I but also internalization and transcytosis in macrophages and aortic endothelial cells, Apo A-I mimetic peptide may be a candidate for functional high-density lipoprotein (HDL) imaging in atherosclerosis. We recently synthesized a novel 24-amino acid Apo A-I mimetic peptide without phospholipids [known as FAMP (FAMP)] which potently removes cholesterol in vitro via specific ABCA1 [6]. In that study using a cholesterol-fed mouse model, we found that FAMP promoted macrophage reverse cholesterol transport (RCT). Moreover, we demonstrated that the unique Apo A-I mimetic peptide FAMP with gallium-68 ($^{68}$Ga) - 1, 4, 7, 10-tetraazaacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) is a promising candidate diagnostic tracer for imaging the atherosclerotic lipid burden [7]. Nonetheless, molecular imaging using $^{68}$Ga-DOTA-FAMP may not be enough for detecting the atherosclerotic burden clearly because $^{68}$Ga has a short physical half-life (68 min).

The aim of the present study was to achieve more sensitive molecular imaging in atherosclerotic lesions. Therefore, FAMP was modified with 4, 11 - bis (carboxymethyl) - 1, 4, 8, 11 - tetraazabicyclo (6.6.2) hexadecane (CB-TE2A) and radiolabeled with copper-64 ($^{64}$Cu) for PET, since $^{64}$Cu has a relatively long physical half-life (12.7 h), and...
molecular imaging using $^{64}$Cu-CB-TE2A-FAMP was compared with that using $^{68}$Ga-DOTA-FAMP.

**Methods**

**Synthesis of CB-TE2A-FAMP and DOTA-FAMP**

FAMP (H-ALEHLFTLYKALELDLLKLL-OH) was modified with CB-TE2A (Macrocyclics, Dallas, TX, USA) (Figure 1A) and DOTA (Strem Chemicals Inc., Newburyport, MA, USA). To a solution of O - (1H-benzotriazol-1-yl) - N, N', N'- tetramethylyuronium hexafluorophosphate (HBTU, 50 µmol) and 1-hydroxybenzotriazole (HOBT, 50 µmol) in N, N - dimethylformamide (DMF, 2 ml) were added CB-TE2A (50 µmol) and DIEA (N, N - disopropylethylamine) 34 µL, and the mixture was stirred at room temperature. After several minutes, this solution was added to 50 µmol/L FAMP resin and stirred at room temperature for 1 hour. The resulting CB-TE2A-FAMP resin was deprotected with a TFA mixture that contained triisopropylsilane (1.0%), 1, 2-ethanediol (2.5%) and water (2.5%) for 2 h. After deprotection, cold diethyl ether was added to the mixture, and the precipitate was collected by centrifugation. Obtained crude CB-TE2A-FAMP was purified by reversed-phase high-performance liquid chromatography (HPLC). Purified CB-TE2A-FAMP was analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; found: m/z 3137.2 (M+H)+, calculated for (M+H)+: 3137.8) (Figure 1B). DOTA-N-hydroxysuccinimidyl (NHS) ester was prepared by the preferential activation of 1 carboxyl group of the DOTA chelator in dimethyl sulfoxide (DMSO), as described previously [7,8].

**Radiolabeling of $^{64}$Cu-CB-TE2A-FAMP and $^{68}$Ga-DOTA-FAMP**

CB-TE2A-FAMP and DOTA-FAMP were radiolabeled with $^{64}$Cu and $^{68}$Ga, respectively, for use in noninvasive PET imaging. Cu-64 was produced by proton-irradiation of a 64Ni electroplated gold disc target using a HM-12S cyclotron (Sumitomo Heavy Industries, Ltd., Tokyo, Japan) [9]. The crude Cu-64 was dissolved in 6 N HCl and purified manually on an ion exchange resin (DOWEX 1X8 100-200 mesh; Muromachi Technos Co., Ltd., Tokyo, Japan) to produce ($^{64}$Cu) CuCl2. 68Ga-DOTA-FAMP was prepared using the method described previously [7,10].

**Animals**

We purchased Japanese white (JW) rabbits from Japan SLC Inc. (Shizuoka, Japan). In addition, myocardial infarction-prone

---

**Figure 1:**

**A)** Scheme for the preparation of 4, 11 - bis (carboxymethyl) - 1, 4, 8, 11 - tetraazabicyclo [6.6.2] hexadecane-Fukuoka University Apo A-I mimetic peptide (CB-TE2A-FAMP). **B)** DOTA-FAMP was separated by reversed-phase high-performance liquid chromatography and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (found: m/z 3137.21 (M + H)+, calculated for (M + H)+: 3137.81).
homozygous Watanabe heritable hyperlipidemic (WHHL-MI) rabbits with total cholesterol >700 mg/dl were provided by Dr Shiomi, Kobe University, Japan. The rabbits were injected with ⁶⁴Cu-CB-TE2A-FAMP (2 nmol per animal) and ⁶⁸Ga-DOTA-FAMP (2-5 nmol per animal). The rabbits were maintained at Fukuoka University, Japan, and experiments were performed at the RIKEN Center for Molecular Imaging Science, Japan. The experiments complied with the regulations of the Committee on Ethics in the Care and Use of Laboratory Animals. The rabbits were housed in rooms maintained at 23 ± 1°C and 55 ± 5% relative humidity with free access to water and standard diet during acclimatization, and were fasted for 24 hr before PET imaging.

PET imaging protocol

Imaging was carried out using a microPETR Focus220 (Siemens, Knoxville, TN, USA) as described previously [7]. Briefly, emission data acquisition was started at the same time as the intravenous administration of ⁶⁴Cu-CB-TE2A-FAMP and ⁶⁸Ga-DOTA-FAMP for 6 h with an energy window of 400-650 keV and a coincidence timing window of 6 ns. The emission images were reconstructed by using filtered back projection with a Ramp filter and a cutoff at the Nyquist frequency. The time course of ⁶⁴Cu activity in the region of the abdominal aortic bifurcation was obtained using ASIPro software included with the microPET system, and the results were adjusted for the background.

Results

Time-dependent attenuation of ⁶⁴Cu-CB-TE2A-FAMP at the abdominal aortic bifurcation

We performed a PET analysis 6 h after the injection of ⁶⁴Cu-CB-TE2A-FAMP at the abdominal aortic bifurcation, when radioactivity should be completely cleared from the circulation. PET images of the abdominal aorta revealed little accumulation of ⁶⁴Cu-CB-TE2A-FAMP in either JW or WHHL-MI rabbits (Figure 2). The time-dependent attenuation of ⁶⁴Cu-CB-TE2A-FAMP in the abdominal aortic bifurcation in WHHL-MI rabbits was mild compared with that in JW rabbits.

PET imaging after injection of the tracer

PET images clearly showed a high uptake of the ⁶⁸Ga-DOTA-FAMP tracer in the aorta of WHHL-MI rabbits (Figure 3A), and little uptake in the aorta of JW rabbits (Figure 3B). On the other hand, PET images showed little uptake of ⁶⁴Cu-CB-TE2A-FAMP in the aorta of either WHHL-MI or JW rabbits (Figure 3C, 3D). Furthermore, the clear uptake of ⁶⁴Cu-CB-TE2A-FAMP in the intestine, liver and bladder was seen in both WHHL-MI and JW rabbits (Figures 3C, 3D and 4A). Finally, there were no uptake in the aorta and the clear uptake of ⁶⁴Cu-CB-TE2A-FAMP in the intestine, liver and bladder at 24 h after the injection in both WHHL-MI and JW rabbits (Figure 4B, 4C).

Discussion

We previously developed a novel PET tracer, Apo A-I mimetic peptide (FAMP) for molecular imaging of atherosclerosis. In this study, we compared the imaging performance of ⁶⁴Cu-CB-TE2A-FAMP and ⁶⁸Ga-DOTA-FAMP in myocardial infarction-prone homozygous Watanabe heritable hyperlipidemic (WHHL-MI) rabbits. Our results indicated that ⁶⁴Cu-CB-TE2A-FAMP showed a lower accumulation in the abdominal aortic bifurcation compared to ⁶⁸Ga-DOTA-FAMP. Further investigations are needed to elucidate the potential diagnostic applications of ⁶⁴Cu-CB-TE2A-FAMP for evaluating atherosclerosis.
peptide FAMP radiolabeled with $^{68}$Ga-DOTA, to specifically image the status of atherosclerotic plaque in WHHL-MI [7]. To achieve more sensitive molecular imaging, FAMP was modified with CB-TE2A and radiolabeled with $^{64}$Cu for PET, and the ability of $^{64}$Cu-TE2A-FAMP to image plaque was compared with that of $^{68}$Ga-DOTA-FAMP. $^{64}$Cu-DOTA-FAMP was interestingly superior to $^{64}$Cu-CB-TE2A-FAMP in atherosclerotic molecular imaging. The selection of a suitable radionuclide and chelator should be important for HDL functioning imaging.

In this study, we selected $^{64}$Cu as a tracer because it has a longer half-life than $^{68}$Ga (12.7 h and 68 min, respectively) for more feasibility clinical use. The half-life of fluorescence-labeled FAMP in blood was about 4 h, according to data on blood clearance of FAMP in mice [6]. Although we thought that a combination of $^{64}$Cu and FAMP could provide superior molecular imaging, PET images showed no uptake of $^{64}$Cu-CB-TE2A-FAMP in the aorta at 6 h after injection (Figure 3C). Since we did not observe any uptake of $^{64}$Cu-CB-TE2A-FAMP in the aorta at 1-2 h after injection (data not shown), we consider that $^{64}$Cu-

![Figure 3](image1.jpg)

Figure 3: Positron emission tomography (PET) imaging after injection of the tracer reveals a high uptake of the $^{68}$Ga-DOTA-FAMP tracer at 1.5 h after injection in the aorta of Watanabe heritable hyperlipidemic (WHHL-MI) rabbits (A), and no uptake of $^{68}$Ga-DOTA-FAMP at 2 h after injection in the aorta of Japanese white (JW) rabbits (B). PET images showed no uptake of $^{64}$Cu-CB-TE2A-FAMP at 6 h after injection in the aorta of both WHHL-MI (C) and JW rabbits (D). $^{68}$Ga-DOTA, gallium-68-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; $^{64}$Cu-CB-TE2A, 4, 11-bis (carboxymethyl)-1, 4, 8, 11-tetraazabicyclo[6.6.2]hexadecane; FAMP, Fukuoka University Apo A-I mimetic peptide.

![Figure 4](image2.jpg)

Figure 4: Positron emission tomography (PET) imaging at 6 h after injection of the tracer reveals a high uptake of $^{64}$Cu-CB-TE2A-FAMP tracer in the intestine, liver and bladder of Watanabe heritable hyperlipidemic (WHHL-MI) rabbits (A). PET imaging at 24 h after injection of the tracer reveals a high uptake of $^{64}$Cu-CB-TE2A-FAMP tracer in the intestine, liver and bladder of WHHL-MI (B) and Japanese white (JW) rabbits (C).
CB-TE2A-FAMP did not provide HDL-functional imaging. Instead, $^{64}$Cu-CB-TE2A-FAMP may be rapidly decomposed, since $^{64}$Cu was excreted to the intestine, liver or urinary bladder in both JW and WHHL-MI rabbits (Figures 3CD and 4A). Previous reports have shown that $^{64}$Cu-DOTA and $^{64}$Cu-TETA complex are moderately unstable in vivo due to the release of uncoordinated $^{64}$Cu by decomposition in the blood or transchelation in the liver, which leads to high uptake in non-target tissues [11,12]. $^{64}$Cu-labeled DOTA/TETA conjugates often show poor blood and liver clearance, high uptake in non-target organs, and increased background radioactivity levels, resulting in reduced imaging sensitivity [13,14]. As for 4Cu-CB-TE2A complexes, Sprague et al. indicated that the $^{64}$Cu-CB-TE2A-Tyr3-octreotate shows improved blood, liver, and kidney clearance compared with the analogous $^{64}$Cu-TETA agent [15]. $^{64}$Cu-CB-TE2A-c is a potential candidate for imaging tumor angiogenesis [16]. In addition, $^{64}$Cu-CB-TE2A-ReCCMSH(Arg11) also showed greatly improved liver and blood clearance as well as higher tumor-to-non-target tissue ratios compared with $^{64}$Cu-DOTA-ReCCMSH (Arg11) [17]. Thus, many researchers have successfully performed molecular imaging using $^{64}$Cu-CB-TE2A. We do not know why $^{64}$Cu-CB-TE2A-FAMP may be rapidly decomposed in vivo at this stage, although we successfully synthesized and purified $^{64}$Cu-CB-TE2A-FAMP as shown in Figure 1. Further studies are needed to solve this issue.

Although $^{68}$Ga-DOTA-FAMP was interestingly superior to $^{64}$Cu-CB-TE2A-FAMP for atherosclerotic molecular imaging, the PET images obtained with $^{68}$Ga-DOTA-FAMP tracer show atherosclerotic plaques more clearly than those obtained using previously reported tracers ($^{18}$F-FDG and $^{111}$In-low-density lipoprotein, etc.) [18-20]. Researchers have successfully performed molecular imaging using $^{64}$Cu-CB-TE2A-FAMP for atherosclerotic molecular imaging, the PET imaging in CVD. JACC Cardiovasc Imaging 6: 1327-1341.

In conclusion, these results demonstrated that FAMP may be a target molecule for atherosclerotic molecular imaging with $^{64}$Ga-DOTA, but not with $^{64}$Cu-CB-TE2A. The selection of a suitable radionuclide and chelator might be important for HDL functioning imaging.

Acknowledgements
None.

Funding
This work was supported by grants-in-aid from the Ministry of Education, Science and Culture of Japan (No. 21590860, No. 24591123), the Fukushima University One-Campus Project (2009, 2010, supported in part by the Ministry of Education, Science and Culture of Japan), a grant-in-aid from the AIG Collaborative Research Institute of Cardiovascular Medicine, Fukushima University, Japan, and NPO Clinical and Applied Science, Fukushima, Japan.

K.S. is a Chief Director and S.M. is a Director of NPO Clinical and Applied Science, Fukushima, Japan. K.S. has an Endowed "Department of Molecular Cardiovascular Therapeutics" supported by MSD, Co. LTD. S.M. and Y.U. belong to the Department of Molecular Cardiovascular Therapeutics, which is supported by MSD, Co. LTD.

References


